The 20th annual BIO CEO & Investor Conference will be held on February 12-13, 2018 at New York Marriott Marquis. It is the largest investor conference focused solely on established and emerging publicly traded and select private biotech companies.
In 2017, over 1,400 predominantly C-level and VP-level attendees from 714 companies and 28 countries engaged in more than 2,600 partnering meetings with investors, and attended 190 company presentations and roundtable discussions. Topics ranged from policy, clinical development and industry trends to fireside chats with CEOs.
The 2018 event looks to be even bigger with the previous year’s success behind the industry. According to BioWorld® Insight1, globally in 2017 biotech firms raised $28.6bn in public offerings (+45% vs. 2016), $7.6bn in other public financing (+25% vs. 2016) and $9.3bn in private biotech investments (+25%).
For companies and investors, this event is paying off. The proprietary BIO One-on-One Partnering™ system, networking opportunities, diverse programming, and exhibiting, make BIO events a must-attend for biotech executives and investors. More than 90% of surveyed attendees from prior events rate partnering sessions and programming as Good or Excellent and returning attendees account for 59% of event registrations2.
Participation in the One-on-One Partnering™ at previous CEO & Investor Conferences correlates with success. Data from the 2016 BIO CEO & Investor Conference One-on-One Partnering™ system was compared to activity in the Strategic Transactions (Informa) database, an industry standard for business intelligence on health care deals. Out of 194 biotech companies, who had One-on-One Partnering™ meetings scheduled at the 2016 Conference, 106 (55%) had a deal listed in Informa Strategic Transactions database since Feb 2016 (All deals between the event date (February 2016) and time of analysis (September 2017) were included):
It is also not surprising that companies who entered into a transaction within 19 months since the event had 83% more meetings scheduled at the event in 2016 than those who did not yet have a transaction in the database (11 vs. 6):
According to BIO CEO & Investor Conference 2017 Attendee Survey Report2, 100% of surveyed investors found multiple companies worth investing into, and 25% of investors who participated in One-on-One Partnering™ at the event in 2016 already entered into a transaction, according to Strategic Transactions database.
Event information is available here.
1 Winter, P. (2017, November 20). IPO market looks to be on target to end year with a flourish. BioWorld® Insight, 25 No. 47, 1-5.
2 Based on self-identification questionnaire; blank responses were excluded from calculation; only verified attendees were counted.